GCIA
CTMX icon

Gabelli & Co Investment Advisers’s CytomX Therapeutics CTMX Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$51.7K Buy
+11,000
New +$55.8K 0.01% 254

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Gabelli & Co Investment Advisers's CTMX Position: Q1 2026 in Review

Gabelli & Co Investment Advisers opened a new position in CytomX Therapeutics (CTMX) in Q1 2026: 11,000 shares worth $51.7K. The stake represents 0.01% of the portfolio and ranks #254 among its holdings.

179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Gabelli & Co Investment Advisers held 11,000 shares of CytomX Therapeutics worth $51.7K as of Q1 2026.
  • CytomX Therapeutics was a new Gabelli & Co Investment Advisers position in Q1 2026.
  • CytomX Therapeutics made up 0.01% of Gabelli & Co Investment Advisers's portfolio in Q1 2026, its #254 holding.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.